Loading…
bioAffinity Technologies, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in BIAF.
▼ -99.4% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $17.70 | $409.50 | $661.95 | $720.00 | |
| P/S | 3.5x | 0.9x | 1.5x | 5.5x | 2792.0x |
| P/B | 2.0x | 0.7x | 5.4x | 2.8x | 1.2x |
| EPS | -$129.90 | -$337.50 | -$409.50 | -$814.50 | |
| Profit margin | -278.75% | -244.10% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PRFXPRF Technologies Ltd. | $0.96 | — | 0.1x | — | -90.37% | $2.92M |
| MTNBMatinas BioPharma Holdings, Inc. | $0.20 | — | 0.7x | — | -141.24% | $2.94M |
| MEDSDataMeds AI, Inc. | $0.96 | — | — | — | — | $2.94M |
| NUWENuwellis, Inc. | $0.89 |
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Company description provided by Yahoo Finance.
| -96.56% |
| -313.41% |
| -169771.25% |
| ROE | -184.17% | -204.87% | -347.41% | -163.47% | -73.84% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| 0.0x |
| — |
| — |
| — |
| $2.82M |
| GNPXGenprex, Inc. | $3.67 | 0.1x | 0.1x | — | -203.86% | $3.01M |
| PPBTPurple Biotech Ltd | $1.68 | — | 0.2x | — | -111.13% | $2.73M |